Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $80
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $58 to $80.
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $58 to $80.